On Thursday morning 08/01/2024 the Johnson & Johnson share started trading at the price of $158.19.
Compared to the closing price on Wednesday 07/31/2024 on BTT of $157.84, this is a gain of 0.22%.
There are 2.41 B shares outstanding in Johnson & Johnson, which values the company at $387.25 B.
Is Johnson & Johnson stock a Buy, Sell or Hold?
Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 49 buy ratings, 32 hold ratings, and 1 sell ratings.What was the 52-week low for Johnson & Johnson stock?
The low in the last 52 weeks of Johnson & Johnson stock was 143.15. According to the current price, Johnson & Johnson is 110.80% away from the 52-week low.What was the 52-week high for Johnson & Johnson stock?
The high in the last 52 weeks of Johnson & Johnson stock was 175.96. According to the current price, Johnson & Johnson is 90.14% away from the 52-week high.What are analysts forecasts for Johnson & Johnson stock?
The 82 analysts offering price forecasts for Johnson & Johnson have a median target of 184.78, with a high estimate of 215.00 and a low estimate of 40.00. The median estimate represents a 85.84 difference from the last price of 158.61.Johnson Johnson Stock Snapshot
158.51
Bid
53.00
Bid Size
158.59
Ask
111.00
Ask Size
8/1/2024
Date
11:24 AM
Zeit
77,834.00
Volume
157.84
Prev. Close
158.19
Öffnen Sie
388.32 B
Market Cap in USD
2.41 B
Number of Shares
157.40
Day Low
159.17
Day High
158.53
143.15
52 Week Low
175.96
52 Week High
158.53
4.70
Dividend in USD
3.00
Dividend Yield
28.32
P/E Ratio
99.83
Free Float in %
5.59
EPS in USD
28.57
Book Value per Share in USD
8.90
Cash Flow per Share in USD
Johnson & Johnson News More News
Historical Prices for Johnson & Johnson
| Date | Öffnen Sie | Schließen Sie | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Johnson & Johnson Analyst Data
Total Analysts: 82
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 40.00
Median: 184.78
Highest: 215.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Johnson & Johnson Analyst Opinions
- Alle
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/30/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 07/30/24 | RBC Capital Markets | Maintained Buy | $175 | |||
| 07/23/24 | Daiwa Securities | Downgraded to Hold | $150 | |||
| 07/19/24 | Goldman Sachs | Maintained Hold | $155 | |||
| 07/18/24 | RBC Capital Markets | Maintained Buy | $175 | |||
| 07/18/24 | Morgan Stanley | Maintained Hold | $169 | |||
| 07/01/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 06/25/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 06/20/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 06/17/24 | RBC Capital Markets | Maintained Buy | $175 | |||
| 06/04/24 | RBC Capital Markets | Maintained Buy | $175 | |||
| 05/22/24 | RBC Capital Markets | Maintained Buy | $175 | |||
| 05/16/24 | RBC Capital Markets | Maintained Buy | $175 | |||
| 05/06/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 04/18/24 | HSBC | Upgraded to Buy | $170 | |||
| 04/17/24 | RBC Capital Markets | Maintained Buy | $175 | |||
| 04/17/24 | Bank of America Merrill Lynch | Maintained Hold | $170 | |||
| 04/15/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 03/13/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 02/28/24 | RBC Capital Markets | Maintained Buy | $181 | |||
| 02/20/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 02/06/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 01/24/24 | Morgan Stanley | Maintained Hold | $169 | |||
| 01/24/24 | RBC Capital Markets | Maintained Buy | $181 | |||
| 01/23/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 01/09/24 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 01/03/24 | Raymond James Financial, Inc. | Maintained Buy | $175 | |||
| 12/13/23 | Wells Fargo & Co | Downgraded to Hold | $163 | |||
| 12/06/23 | RBC Capital Markets | Maintained Buy | $181 | |||
| 12/01/23 | RBC Capital Markets | Maintained Buy | $178 | |||
| 12/01/23 | UBS | Upgraded to Buy | $180 | |||
| 11/20/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 11/17/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 10/23/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 10/18/23 | Morgan Stanley | Maintained Hold | $171 | |||
| 10/18/23 | Raymond James Financial, Inc. | Maintained Buy | $172 | |||
| 10/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 10/12/23 | Barclays Capital | Maintained Hold | $162 | |||
| 10/11/23 | Morgan Stanley | Maintained Hold | $174 | |||
| 10/09/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 10/05/23 | RBC Capital Markets | Maintained Buy | $178 | |||
| 10/02/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 09/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 09/08/23 | Barclays Capital | Maintained Hold | $158 | |||
| 09/06/23 | HSBC | Maintained Sell | $175 | |||
| 09/05/23 | Cantor Fitzgerald | Maintained Buy | $215 | |||
| 09/05/23 | Raymond James Financial, Inc. | Maintained Buy | $179 | |||
| 08/31/23 | Wells Fargo & Co | Maintained Buy | $186 | |||
| 08/31/23 | Morgan Stanley | Maintained Hold | $172 | |||
| 08/30/23 | Cantor Fitzgerald | Maintained Buy | $215 |
Johnson & Johnson Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 88,488 | 91,132 | 94,377 | 98,142 | 102,410 |
| Dividend | 4.65 | 5.01 | 5.25 | 5.77 | 6.07 |
| Dividend Yield (in %) | 2.94 % | 3.16 % | 3.31 % | 3.64 % | 3.83 % |
| EPS | 10.01 | 10.69 | 11.30 | 11.73 | 12.19 |
| P/E Ratio | 15.83 | 14.81 | 14.02 | 13.50 | 12.99 |
| EBIT | 27,657 | 29,568 | 30,983 | 31,811 | 33,978 |
| EBITDA | 31,955 | 33,778 | 35,671 | 38,738 | 38,211 |
| Net Profit | 24,184 | 25,697 | 27,019 | 27,430 | 28,683 |
| Net Profit Adjusted | 24,184 | 25,697 | 27,019 | 27,430 | 28,683 |
| Pre-Tax Profit | 29,461 | 30,869 | 32,451 | 32,908 | 34,456 |
| Net Profit (Adjusted) | 24,500 | 26,620 | 28,153 | 26,287 | 26,862 |
| EPS (Non-GAAP) ex. SOE | 9.90 | 11.16 | 11.87 | 11.91 | - |
| EPS (GAAP) | 7.82 | 8.86 | 10.08 | 9.23 | 9.43 |
| Gross Income | 65,915 | 67,964 | 70,295 | 73,585 | 76,852 |
| Cash Flow from Investing | -7,820 | -14,975 | -15,292 | -20,131 | -20,816 |
| Cash Flow from Operations | 25,557 | 27,033 | 27,291 | 28,324 | 30,291 |
| Cash Flow from Financing | -7,820 | -14,975 | -15,292 | -20,131 | -20,816 |
| Cash Flow per Share | 10.67 | 11.60 | 12.78 | 12.38 | 12.67 |
| Free Cash Flow | 22,421 | 23,720 | 24,559 | 26,961 | 11,847 |
| Free Cash Flow per Share | 7.42 | 7.30 | 7.28 | 4.82 | 4.86 |
| Book Value per Share | 29.64 | 32.58 | 36.07 | 36.75 | 39.19 |
| Net Debt | 1,055 | -11,377 | -24,053 | -30,905 | -38,410 |
| Research & Development Exp. | 15,783 | 15,626 | 15,963 | 16,464 | 17,026 |
| Capital Expenditure | 4,172 | 4,192 | 4,264 | 4,408 | 4,368 |
| Selling, General & Admin. Exp. | 22,467 | 22,859 | 23,522 | 24,365 | 25,066 |
| Shareholder’s Equity | 74,984 | 82,100 | 89,806 | 86,215 | 101,024 |
| Total Assets | 183,857 | 190,538 | 196,967 | 188,176 | 202,662 |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 17 | 17 | 20 | 20 |
| Average Estimate | - | 2.206 USD | 2.323 USD | 10.006 USD | 10.694 USD |
| Year Ago | - | 1.999 USD | 1.682 USD | 5.593 USD | - |
| Datum veröffentlichen | - | 10/15/2024 | 1/28/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 15 | 15 | 19 | 19 |
| Average Estimate | - | 22,127 USD | 22,444 USD | 88,488 USD | 91,132 USD |
| Year Ago | - | 21,345 USD | 21,391 USD | 85,152 USD | - |
| Datum veröffentlichen | - | 10/15/2024 | 1/28/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Verkauf | 85,152.00 | 95,015.00 | 93,758.00 | 82,572.00 | 82,113.00 | 81,534.00 | 76,481.00 |
| Change of sales in % | -10.38 | 1.34 | 13.55 | 0.56 | 0.71 | 6.61 | 6.32 |
| Gross profit on sales | 58,722.00 | 64,297.00 | 63,884.00 | 54,574.00 | 54,978.00 | 54,348.00 | 51,374.00 |
| Gross profit on sales change in % | -8.67 | 0.65 | 17.06 | -0.73 | 1.16 | 5.79 | 2.14 |
| Operating income | 22,162.00 | 24,780.00 | 24,481.00 | 20,468.00 | 21,550.00 | 21,253.00 | 19,565.00 |
| Operating income change in % | -10.56 | 1.22 | 19.61 | -5.02 | 1.40 | 8.63 | -8.36 |
| Income before tax | 15,062.00 | 21,725.00 | 22,776.00 | 16,497.00 | 17,328.00 | 17,999.00 | 17,673.00 |
| Income before tax change in % | -30.67 | -4.61 | 38.06 | -4.80 | -3.73 | 1.84 | -10.76 |
| Income after tax | 14,169.00 | 17,941.00 | 20,878.00 | 14,714.00 | 15,119.00 | 15,297.00 | 1,300.00 |
| Income after tax change in % | -21.02 | -14.07 | 41.89 | -2.68 | -1.16 | 1,076.69 | -92.14 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 98,784.00 | 110,574.00 | 107,995.00 | 111,616.00 | 98,257.00 | 93,202.00 | 97,143.00 |
| Long-term liabilities per share | 21.81 | 20.96 | 23.88 | 26.26 | 23.66 | 23.28 | 24.83 |
| Equity | 68,774.00 | 76,804.00 | 74,023.00 | 63,278.00 | 59,471.00 | 59,752.00 | 60,160.00 |
| Equity change in % | -10.46 | 3.76 | 16.98 | 6.40 | -0.47 | -0.68 | -14.57 |
| Balance sheet total | 167,558.00 | 187,378.00 | 182,018.00 | 174,894.00 | 157,728.00 | 152,954.00 | 157,303.00 |
| Balance sheet total change in % | -10.58 | 2.94 | 4.07 | 10.88 | 3.12 | -2.76 | 11.40 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 33.26 | 35.67 | 35.06 | 30.92 | 30.59 | 29.88 | 27.86 |
| P/E ratio (year end quote, basic EPS) | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 | 22.69 | 297.28 |
| P/E ratio (year end quote, diluted EPS) | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 | 22.69 | 297.28 |
| P/E ratio (year end quote) | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 | 22.69 | 297.28 |
| Dividend yield in % | 3.00 | 2.52 | 2.45 | 2.53 | 2.57 | 2.78 | 2.38 |
| Equity ratio in % | 41.04 | 40.99 | 40.67 | 36.18 | 37.70 | 39.07 | 38.24 |
| Debt ratio in % | 58.96 | 59.01 | 59.33 | 63.82 | 62.30 | 60.93 | 61.76 |
Johnson & Johnson Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Broadhurst Vanessa | 07/07/2024 | 5,018.00 | 19,834.00 | 147.16 | Sell | No |
| Broadhurst Vanessa | 07/07/2024 | 9,809.00 | 24,852.00 | n/a | Buy | No |
| REED JOHN C | 04/30/2024 | 10,984.00 | 11,577.00 | 144.59 | Sell | No |
| REED JOHN C | 04/30/2024 | 22,255.00 | 22,561.00 | n/a | Buy | No |
| Broadhurst Vanessa | 03/12/2024 | 8,891.00 | 15,043.00 | 162.16 | Sell | No |
| Wengel Kathryn E | 02/12/2024 | 333.00 | 82,265.87 | 157.85 | Sell | No |
| Wolk Joseph J | 02/12/2024 | 773.00 | 68,890.00 | 157.85 | Sell | No |
| Forminard Elizabeth | 02/12/2024 | 236.00 | 8,340.00 | 157.85 | Sell | No |
| Taubert Jennifer L | 02/12/2024 | 666.00 | 154,851.00 | 157.85 | Sell | No |
| Decker Robert J | 02/12/2024 | 86.00 | 18,973.00 | 157.85 | Sell | No |
| Wengel Kathryn E | 02/12/2024 | 651.00 | 82,598.87 | n/a | Buy | No |
| Wolk Joseph J | 02/12/2024 | 1,780.00 | 69,663.00 | n/a | Buy | No |
| Forminard Elizabeth | 02/12/2024 | 651.00 | 8,576.00 | n/a | Buy | No |
| Taubert Jennifer L | 02/12/2024 | 1,302.00 | 155,517.00 | n/a | Buy | No |
| Decker Robert J | 02/12/2024 | 313.00 | 19,059.00 | n/a | Buy | No |
| Duato Joaquin | 02/11/2024 | 15,900.00 | 361,339.00 | 157.40 | Sell | No |
| Decker Robert J | 02/11/2024 | 523.00 | 18,746.00 | 157.40 | Sell | No |
| Broadhurst Vanessa | 02/11/2024 | 2,136.00 | 23,735.00 | 157.40 | Sell | No |
| Forminard Elizabeth | 02/11/2024 | 1,034.00 | 7,925.00 | 157.40 | Sell | No |
| Schmid Timothy | 02/11/2024 | 2,887.00 | 12,791.00 | 157.40 | Sell | No |
| Taubert Jennifer L | 02/11/2024 | 13,403.00 | 154,215.00 | 157.40 | Sell | No |
| Fasolo Peter | 02/11/2024 | 7,019.00 | 111,625.00 | 157.40 | Sell | No |
| Wolk Joseph J | 02/11/2024 | 10,816.00 | 67,883.00 | 157.40 | Sell | No |
| Swanson James D. | 02/11/2024 | 1,695.00 | 14,318.00 | 157.40 | Sell | No |
| Wengel Kathryn E | 02/11/2024 | 7,066.00 | 81,947.87 | 157.40 | Sell | No |
Johnson Johnson Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Johnson & Johnson | 4.70 | 3.00 | USD |
| 2022 | Johnson & Johnson | 4.45 | 2.52 | USD |
| 2021 | Johnson & Johnson | 4.19 | 2.45 | USD |
| 2020 | Johnson & Johnson | 3.98 | 2.53 | USD |
| 2019 | Johnson & Johnson | 3.75 | 2.57 | USD |
| 2018 | Johnson & Johnson | 3.54 | 2.78 | USD |
| 2017 | Johnson & Johnson | 3.32 | 2.38 | USD |
| 2016 | Johnson & Johnson | 3.15 | 2.73 | USD |
| 2015 | Johnson & Johnson | 2.95 | 2.87 | USD |
| 2014 | Johnson & Johnson | 2.76 | 2.63 | USD |
| 2013 | Johnson & Johnson | 2.59 | 2.80 | USD |
| 2012 | Johnson & Johnson | 2.40 | 3.45 | USD |
| 2011 | Johnson & Johnson | 2.25 | 3.43 | USD |
| 2010 | Johnson & Johnson | 2.11 | 3.41 | USD |
| 2009 | Johnson & Johnson | 1.93 | 3.00 | USD |
| 2008 | Johnson & Johnson | 1.79 | 3.06 | USD |
| 2007 | Johnson & Johnson | 1.62 | 2.43 | USD |
| 2006 | Johnson & Johnson | 1.46 | 2.21 | USD |
| 2005 | Johnson & Johnson | 1.27 | 2.11 | USD |
| 2004 | Johnson & Johnson | 1.09 | 1.72 | USD |
| 2003 | Johnson & Johnson | 0.92 | 1.82 | USD |
| 2002 | Johnson & Johnson | 0.79 | 1.47 | USD |
| 2001 | Johnson & Johnson | 0.70 | 1.17 | USD |
| 2000 | Johnson & Johnson | 0.62 | 1.18 | USD |
| 1999 | Johnson & Johnson | 0.55 | 1.18 | USD |
*Yield of the Respective Date
Johnson & Johnson Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.206 USD | Q3 2024 Earnings Release | 10/15/2024 |
| Earnings Report | 2.323 USD | Q4 2024 Earnings Release | 01/28/2025 |
| Earnings Report | 2.678 USD | Q1 2025 Earnings Release | 04/22/2025 |
| Earnings Report | 2.750 USD | Q2 2025 Earnings Release | 07/22/2025 |
Johnson & Johnson Past Events
| Event | Actual EPS | Info | Date |
|---|
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Moody’s Daily Credit Risk Score
Johnson & Johnson Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.83 |
| The Vanguard Group, Inc. | 9.53 |
| Vanguard Group, Inc. (Subfiler) | 9.09 |
| State Street Corp. | 5.55 |
| SSgA Funds Management, Inc. | 5.53 |
| Vanguard Total Stock Market ETF | 3.16 |
| BlackRock Fund Advisors | 2.93 |
| Vanguard 500 Index Fund | 2.57 |
| Geode Capital Management LLC | 2.22 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| State Farm Investment Management Corp. | 1.32 |
| Fidelity 500 Index Fund | 1.22 |
| Norges Bank (13F) | 1.08 |
| iShares Core S&P 500 ETF | 1.06 |
| Government Pension Fund - Global (The) | 1.05 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Johnson & Johnson Management
| Name | Job |
|---|---|
| Joaquin Duato | Chairman & Chief Executive Officer |
| Robert J. Decker | Chief Accounting Officer & Controller |
| Ronald A. Kapusta | Chief Accounting Officer & Controller |
| Frederic H. Moll | Chief Development Officer |
| William N. Hait | Chief External Innovation & Executive VP-Medical |
| Joseph J. Wolk | Chief Financial Officer & Executive Vice President |
| Paul Ruh | Chief Financial Officer-Consumer Health |
| Peter M. Fasolo | Chief Human Resources Officer & Executive VP |
| James D. Swanson | Chief Information Officer & Executive VP |
| Kathryn E. Wengel | Chief Technical Operations & Risk Officer |
| Jonathan Sheh | Director-Workplace Experience |
| Jennifer L. Taubert | EVP & Worldwide Chairman-Innovative Medicine |
| Timothy Schmid | Executive Vice President & Chairman-Worldwide |
| Elizabeth Forminard | Executive Vice President & General Counsel |
| John C. Reed | Executive Vice President-Innovative Medicine |
| Michael Bzdak | Global Dir-Employee Engagement-Global Cmnty Impact |
| George Davy | Global HR Director |
| Caroline Tillett | Global Head-Consumer Health |
| Juliana Clawson | Head-Global Quality & Compliance |
| Neil Ackerman | Head-Innovation, Global Supply & Transformation |
| Jennifer A. Doudna | Independent Director |
| Mark B. McClellan | Independent Director |
| Paula A. Johnson | Independent Director |
| Mark Alan Weinberger | Independent Director |
| Mary C. Beckerle | Independent Director |
| D. Scott Davis | Independent Director |
| Eugene A. Woods | Independent Director |
| Nadja Y. West | Independent Director |
| Anne M. Mulcahy | Independent Director |
| Darius Adamczyk | Independent Director |
| Hubert Joly | Independent Director |
| Marillyn A. Hewson | Lead Independent Director |
| Thomas J. Spellman | Secretary |
| Marc Larkins | Secretary & Vice President-Governance |
| Meredith Stevens | Vice President |
| Jessica Moore | Vice President-Investor Relations |
| William E. Cohn | Vice President-Medical Devices |
| Lisa Paley | Vice President-US Sales |